Cargando…

Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians

Detalles Bibliográficos
Autores principales:	Ji, Hong-Long, Wagener, Brant M., Ness, Timothy J., Zhao, Runzhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276553/ https://www.ncbi.nlm.nih.gov/pubmed/34271164 http://dx.doi.org/10.1016/j.pupt.2021.102055

Ejemplares similares

Fibrinolytic therapy for COVID-19: a review of case series
por: Ji, Hong-Long, et al.
Publicado: (2021)

Meta-Analysis of Preclinical Studies of Fibrinolytic Therapy for Acute Lung Injury
por: Liu, Cong, et al.
Publicado: (2018)

Role of Fibrinolytic Enzymes in Anti-Thrombosis Therapy
por: Altaf, Farwa, et al.
Publicado: (2021)

Cardiac arrest caused by nafamostat mesilate
por: Kim, Hyo Shik, et al.
Publicado: (2016)

Potential of heparin and nafamostat combination therapy for COVID‐19
por: Asakura, Hidesaku, et al.
Publicado: (2020)

Crystal structure of nafamostat dimesylate
por: Fujii, Isao
Publicado: (2021)

Nafamostat: Hyperkalaemia: case report
Publicado: (2021)

STUDIES OF THE PLASMIN SYSTEM : II. INHIBITION OF PLASMIN BY SERUM OR PLASMA
por: Norman, Philip S.
Publicado: (1958)

Purification and characterization of mutant miniPlasmin for thrombolytic therapy
por: Lin, Xiaotao, et al.
Publicado: (2013)

Fibrinolytic Therapy in Acute Stroke
por: Millán, Mònica, et al.
Publicado: (2010)

Plasmin and Articular Cartilage
por: Chrisman, O. Donald, et al.
Publicado: (1962)

STUDIES OF THE PLASMIN SYSTEM : III. PHYSICAL PROPERTIES OF THE TWO PLASMIN INHIBITORS IN PLASMA
por: Norman, Philip S., et al.
Publicado: (1958)

Elevation of Plasmin-α2-plasmin Inhibitor Complexes in Patients with AL Amyloidosis
por: Miyazaki, Kanji, et al.
Publicado: (2018)

Fibrinolytic niche is required for alveolar type 2 cell-mediated alveologenesis via a uPA-A6-CD44(+)-ENaC signal cascade
por: Ali, Gibran, et al.
Publicado: (2021)

Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis
por: Kim, Joo-Hee, et al.
Publicado: (2021)

Perspective on fibrinolytic therapy in COVID-19: the potential of inhalation therapy against suppressed-fibrinolytic-type DIC
por: Asakura, Hidesaku, et al.
Publicado: (2020)

Utility and safety of nafamostat mesilate for anticoagulation in dogs
por: Isayama, Noriko, et al.
Publicado: (2022)

Successful Fibrinolytic Therapy in a Challenging Obstructive Prosthetic Mitral Valve Thrombosis
por: Essa, Amr, et al.
Publicado: (2020)

Plasmin inhibitor interactions. The effectiveness of alpha2-plasmin inhibitor in the presence of alpha2-macroglobulin
Publicado: (1977)

Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation
por: Han, Sang Jin, et al.
Publicado: (2011)

Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy
por: Jang, Sukbin, et al.
Publicado: (2020)

A case of hemothorax secondary to intrapleural fibrinolytic therapy: Considerations for use of fibrinolytics in high-risk patients
por: Narula, Naureen, et al.
Publicado: (2021)

Heparin and Arginine Based Plasmin Nanoformulation for Ischemic Stroke Therapy
por: Aamir, Ramsha, et al.
Publicado: (2021)

Identification and Characterization of Plasmin-Independent Thrombolytic Enzymes
por: Hassan, Md. Mehedi, et al.
Publicado: (2020)

Nafamostat: Off-label use and hyperkalaemia: case report
Publicado: (2020)

Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
por: Ghali, George Zaki, et al.
Publicado: (2020)

Heparin/nafamostat: Bleeding and subcutaneous haematoma: case report
Publicado: (2022)

Heparin/nafamostat: Bleeding, hyperkaelemia and haemothorax: case report
Publicado: (2021)

Cardiopulmonary arrest caused by nafamostat mesylate during hemodialysis
por: Shioya, Nobuki, et al.
Publicado: (2022)

Extended Dwell Time Improves Results of Fibrinolytic Therapy for Complex Pleural Effusions
por: Patino, Sanja H, et al.
Publicado: (2020)

In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity
por: Fujimoto, Kazuhiro J., et al.
Publicado: (2022)

Fibrinolytic therapy for parapneumonic empyema during pregnancy
por: Ulutas, Hakki, et al.
Publicado: (2011)

VATS and Intrapleural Fibrinolytic Therapy for Parapneumonic Empyema
por: Ohara, Gen, et al.
Publicado: (2018)

Efficacy of standardizing fibrinolytic therapy for parapneumonic effusion
por: James, Charles A., et al.
Publicado: (2022)

The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation
por: Lee, Jae Ha, et al.
Publicado: (2022)

Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation
por: Takahashi, Wakana, et al.
Publicado: (2021)

Application of nafamostat mesylate for anticoagulation in hemoperfusion therapy in patients with bromadiolone poisoning: Case reports
por: Qian, Weiwei, et al.
Publicado: (2023)

THE INACTIVATION OF COMPLEMENT AND ITS COMPONENTS BY PLASMIN
por: Pillemer, Louis, et al.
Publicado: (1953)

Does plasmin have anticoagulant activity?
por: Hoover-Plow, Jane
Publicado: (2010)

Assessing Plasmin Generation in Health and Disease
por: Miszta, Adam, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_chd4677qpl4g5rk60v6mje18g9